Recommendation of the President – Minjuvi (tafasitamab)
On 25 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 51/2025 on the appraisal Minjuvi (tafasitamab) under the B.12.FM drug program. Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)